Wed, Aug 20, 2014, 8:58 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Affymax, Inc. (AFFY) Message Board

  • groy_1998 groy_1998 Sep 27, 2013 9:50 AM Flag

    news

    @ mdlinx

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • You guys are being silly. Suddenly, a word for word repeat of a Jan. release pops up somewhere, and you can't see it's a mistake? The drug was removed from the market, so I doubt they'd be doing anything to re-establish a J-code that was already established.

      Still holding a large position at $1.16, but until proven wrong, I won't get overly excited.

    • Here's the whole thing.

      Affymax and Takeda announce permanent J-code for OMONTYS (peginesatide) injection is in effect Full Text
      Takeda Pharmaceuticals U.S.A., 09/25/2013
      Affymax, and Takeda Pharmaceuticals U.S.A.,announced that the J–code assigned by the Centers for Medicare and Medicaid Services (CMS) for OMONTYS (peginesatide) Injection is now effective. This permanent OMONTYS–specific billing code, J0890, will continue to provide for streamlined reimbursement for dialysis organizations prescribing OMONTYS.

      • 1 Reply to ymcd56
      • That news is from January, 2013. ???

        Affymax and Takeda Announce Permanent J-Code for OMONTYS® (peginesatide) Injection is in Effect
        Code J0890 Effective As of January 1, 2013
        PALO ALTO, Calif. & DEERFIELD, Ill.--(BUSINESS WIRE)-- Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) today announced that the J-code assigned by the Centers for Medicare and Medicaid Services (CMS) for OMONTYS® (peginesatide) Injection is now effective. This permanent OMONTYS-specific billing code, J0890, will continue to provide for streamlined reimbursement for dialysis organizations prescribing OMONTYS. OMONTYS is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia available to the adult dialysis patient population with chronic kidney disease (CKD) in the United States (U.S.).
        "We are excited by the strong level of interest in the dialysis community for OMONTYS," said John Orwin, chief executive officer, Affymax. "We believe the J-code complements our efforts to make this once-monthly therapy broadly available to the dialysis community, and importantly, to appropriate patients."
        According to Nicole Mowad-Nassar, vice president, marketing at Takeda, "We are pleased to have an effective J-code in place approximately nine months following the approval of OMONTYS."
        OMONTYS was approved by the U.S. Food and Drug Administration (FDA) on March 27, 2012, for the treatment of anemia due to CKD in adult patients on dialysis. OMONTYS is not indicated and is not recommended for use in patients with CKD not on dialysis, in patients receiving treatment for cancer and whose anemia is not due to CKD, or as a substitute for red blood cell (RBC) transfusions in patients who require immediate correction of anemia. OMONTYS has not been shown to improve symptoms, physical functioning, or health-related quality of life. Please see Important Safety Information including Boxed WARNINGS below.
        Information on OMONTYS Reimbursement Support

        Customers seeking additional information about accessing the product can refer to the OMONTYS Reimbursement Access Support (RAS) program. RAS offers comprehensive reimbursement access, and support services for healthcare providers. For more information please call 1-855-GOMONTYS (1-855-466-6689) for more information.

        Sentiment: Hold

    • My post seems to have gone MIA.E.Kovak left out the important part.That was dated 2 days ago.Nice work Groy.

    • Up 3 cents "so far" on this news

      Sentiment: Strong Buy

    • confusing website, it appears that althought they date articles as recent, the actual articles are older. Busy this morning and cant read through, first glance may not be what it seems.

    • Affymax, and Takeda Pharmaceuticals U.S.A.,announced that the J–code assigned by the Centers for Medicare and Medicaid Services (CMS) for OMONTYS (peginesatide) Injection is now effective. This permanent OMONTYS–specific billing code, J0890, will continue to provide for streamlined reimbursement for dialysis organizations prescribing OMONTYS.

 
AFFY
0.108+0.003(+2.86%)Aug 20 3:51 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.